Literature DB >> 22217576

Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management.

Hideyuki Akaza1, Peter Carroll, Matthew R Cooperberg, Shiro Hinotsu.   

Abstract

This report summarizes the presentations and discussions that took place at the Fifth Joint Meeting of J-CaP and CaPSURE held in Tokyo, Japan, in July 2011. The J-CaP and CaPSURE Joint Initiative was established in 2007 with the objective of analyzing, reviewing, comparing and contrasting data on prostate cancer patients from Japan and the USA within the two important large-scale, longitudinal, observational databases-J-CaP and CaPSURE. Since its inception, the initiative has reviewed a wide range of topics and generated valuable data on the patterns of prostate cancer treatment and patient outcomes in the two geographical regions. The objectives of this 5th Joint Meeting were to provide an update on the current status of the J-CaP and CaPSURE databases, and also to discuss perspectives from a range of other Asian countries-Japan, China, Indonesia and Korea-on the use of androgen deprivation therapy for prostate cancer. The collaborators recognize that large databases, such as J-CaP and CaPSURE, provide valuable 'real-world' information, to complement data from clinical trials, which can help to advance the clinical management of prostate cancer patients worldwide. It is anticipated that in the near future, the Joint Initiative will expand globally to include patient registries from other countries so that best practice can be shared and regional differences in patients, treatments and outcomes can be explored.

Entities:  

Mesh:

Year:  2012        PMID: 22217576     DOI: 10.1093/jjco/hyr194

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

1.  Ten-year outcomes of I¹²⁵ low-dose-rate brachytherapy for clinically localized prostate cancer: a single-institution experience in Japan.

Authors:  Narihiko Hayashi; Koji Izumi; Futoshi Sano; Yasuhide Miyoshi; Hiroji Uemura; Takeo Kasuya; Akiko Mukai; Masayuki Hata; Tomio Inoue
Journal:  World J Urol       Date:  2015-01-23       Impact factor: 4.226

Review 2.  Prostate cancer trends in Asia.

Authors:  Hideyuki Akaza; Mizuki Onozawa; Shiro Hinotsu
Journal:  World J Urol       Date:  2016-09-19       Impact factor: 4.226

3.  Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort.

Authors:  Teruo Inamoto; Haruhito Azuma; Shiro Hinotsu; Taiji Tsukamoto; Mototsugu Oya; Osamu Ogawa; Tadaichi Kitamura; Suzuki Kazuhiro; Seiji Naito; Mikio Namiki; Kazuo Nishimura; Yoshihiko Hirao; Michiyuki Usami; Masaru Murai; Hideyuki Akaza
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-28       Impact factor: 4.553

4.  Development of prostate cancer research database with the clinical data warehouse technology for direct linkage with electronic medical record system.

Authors:  In Young Choi; Seungho Park; Bumjoon Park; Byung Ha Chung; Choung-Soo Kim; Hyun Moo Lee; Seok-Soo Byun; Ji Youl Lee
Journal:  Prostate Int       Date:  2013-06-30

5.  The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer.

Authors:  Xu Guo; Chao Zhang; Qi Guo; Yao Xu; Guowei Feng; Lili Li; Xiuxin Han; Feng Lu; Yulin Ma; Xin Wang; Guowen Wang
Journal:  Cancer Manag Res       Date:  2018-06-22       Impact factor: 3.989

Review 6.  Asian trends in primary androgen depletion therapy on prostate cancer.

Authors:  Hideyuki Akaza
Journal:  Cancer Biol Med       Date:  2013-12       Impact factor: 4.248

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.